Retrospective comparison of neutropenia in children with ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2388-2395

  Milano Bausset, Emilie ^a   Gaudart, Jean ^b,c   Rome, Angelique ^a   Coze, Carole ^a   Gentet, Jean Claude ^a   Padovani, Laetitia ^a   Lacarelle, Bruno ^a   André, Nicolas ^a  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

chemotherapy; children; Ewing sarcoma; neutropenia; oncology; pegylated G CSF

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILD HOSPITALIZATION; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; ERYTHROCYTE TRANSFUSION; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE PAIN; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; TREATMENT DURATION;

EID: 74549160577     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.013     Document Type: Article

References (23)

1. Lord B.I., Bronchud M.H., Owens S., et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A 86 (1989) 9499-9503
2. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 24 (2006) 3187-3205
3. Welte K., Gabrilove J., Bronchud M.H., et al. Filgrastim (r-metHuG-CSF): The first 10 years. Blood. 88 (1996) 1907-1929
4. Molineux G. Pegylation: Engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev. 28 Suppl A (2002) 13-16
5. Willis F., and Pettengell R. Pegfilgrastim. Expert Opin Biol Ther. 2 (2002) 985-992
6. Aapro M.S., Cameron D.A., Pettengell R., et al., Euro-pean Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 42 (2006) 2433-2453
7. Pinto L., Liu Z., Doan Q., et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: A meta-analysis of randomized controlled trials. Curr Med Res Opin. 23 (2007) 2283-2295
8. te Poele E.M., Kamps W.A., Tamminga R.Y., et al. Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol. 27 (2005) 627-629
9. Wendelin G., Lackner H., Schwinger W., et al. Once-percycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol. 27 (2005) 449-451
10. André N., Kababri M.E., Bertrand P., et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs. 18 (2007) 277-281
11. André N., Milano E., Rome A., and Gentet J.C. Safety of pegfilgrastim in children. Ann Pharmacother. 42 (2008) 290
12. Borinstein S.C., Pollard J., Winter L., and Hawkins D.S. Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer 53 (2009) 375-378
13. Beaupain B., Leblanc T., Reman O., et al., French SCN Registry, Service d'Hémato Oncologie Pédiatrique. Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer 53 (2009) 1068-1073
14. Dallorso S., Berger M., Caviglia I., et al. Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. Bone Marrow Transplant. 42 (2008) 507-513
15. Merlin E., Zohar S., Jérôme C., et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: Do the advantages of pegfilgrastim really translate into clinical benefit?. Bone Marrow Transplant. 43 (2009) 919-925
16. Juergens C., Weston C., Lewis I., et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47 (2006) 22-29
17. Neulasta (pegfilgrastim) [prescribing information] [in French]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/neulasta/H-420-PI-fr.pdf Accessed October 21, 2009
18. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 73 (1986) 13-22
19. Prentice R.L., and Zhao L.P. Estimating equations for parameters in means and covariances of multivariate discrete and continuous responses. Biometrics 47 (1991) 825-839
20. Vose J.M., Crump M., Lazarus H., et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 21 (2003) 514-519
21. Green M.D., Koelbl H., Baselga J., et al., International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 14 (2003) 29-35
22. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 20 (2002) 727-731
23. Bernstein M.L., Devidas M., Lafreniere D., et al., Pediatric Oncology Group, Children's Cancer Group Phase II Study 9457, Children's Oncology Group. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457-a report from the Children's Oncology Group. J Clin Oncol. 24 (2006) 152-159